{"id":"W2969017474","doi":"10.1634/theoncologist.2019-0321","title":"A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229)","year":2019,"lang":"en","type":"article","venue":"The Oncologist","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Toronto; BC Cancer Agency","funders":"","keywords":"Medicine; Durvalumab; Trastuzumab; Internal medicine; Metastatic breast cancer; Oncology; Breast cancer; Clinical endpoint; Pertuzumab; Cancer; Response Evaluation Criteria in Solid Tumors; Adverse effect; Progressive disease; Chemotherapy; Gastroenterology; Clinical trial; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001439155,0.0001617932,0.0005879755,0.000211965,0.00002971043,0.00001424927,0.0002192216,0.00008072417,0.0004294813],"category_scores_gemma":[0.0001289515,0.0001021835,0.00005569637,0.0007204659,0.0003655858,0.00008136027,0.00005225372,0.0005203962,0.00002901439],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001374039,"about_ca_system_score_gemma":0.001235801,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.009825579,"about_ca_topic_score_gemma":0.006353996,"domain_scores_codex":[0.9978405,0.0004951544,0.0004329237,0.0002847735,0.0005963234,0.0003503102],"domain_scores_gemma":[0.9988879,0.0003526602,0.0001825908,0.0003486449,0.0001580714,0.00007013085],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6118274,0.03997851,0.06717616,0.001215583,0.0007212221,0.0009163432,0.01341672,0.00083722,0.009461508,0.002148534,0.00158797,0.2507128],"study_design_scores_gemma":[0.7113746,0.04640257,0.2257129,0.001826708,0.0003125333,0.0002240172,0.0049155,0.00303117,0.004181256,0.000616808,0.0009084901,0.0004934141],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9876633,0.0001149425,0.00002390698,0.004450496,0.0001434407,0.003124044,0.00008192358,0.00001650437,0.004381408],"genre_scores_gemma":[0.998541,0.00008056233,0.00009326557,0.0001565963,0.00005755985,0.000375214,0.00002200162,0.00002536032,0.0006484392],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2502193,"threshold_uncertainty_score":0.9967681,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05384371908796651,"score_gpt":0.4257430872117402,"score_spread":0.3718993681237737,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}